



RESI REDEFINING
EARLY STAGE
INVESTMENTS

EUROPE 2024

June 17 | Barcelona Catalonia Spain
June 18-19 | Virtual Partnering



PRESENTED BY



ONSITE GUIDE

Early stage investors, fundraising CEOs,
scientist entrepreneurs, strategic partners, and service providers
now have an opportunity to **Make a Compelling Connection**

CO-ORGANIZERS



RESIConference.com | Hilton Diagonal Mar Barcelona
#RESI #RESIEUROPE

CONTENT

RESI EUROPE 2024

• Welcome to RESI	1
• Floor Plan	2
• RESI Agenda	6
• Sponsors & Exhibitors	7
• Media Partners	18
• Partnering Forum	19
• Investor Panels	20
• Investor Panel Speakers	23
• Innovator's Pitch Challenge	33
• Entrepreneur's Workshops	46

WELCOME TO RESI



Welcome to RESI Europe 2024 in Barcelona! Life Science Nation (LSN) is thrilled to welcome the global community of early-stage investors, strategic partners, and life science entrepreneurs to Redefining Early Stage Investments (RESI) Europe conference at the Hilton Diagonal Mar Hotel in Barcelona. This year's event holds special significance as it showcases the burgeoning life science innovation ecosystem in Europe.

The schedule for RESI Europe on Monday, June 17, is brimming with exciting opportunities for attendees. Each hour will feature insightful investor panels, two Innovator's Pitch Challenge (IPC) tracks, and informative workshops. The IPC will give early-stage finalists the chance to pitch directly to a live audience and a panel of esteemed investor judges. Don't forget to 'invest' your RESI Cash, tucked into your notebook at registration, for your favorite pitch companies – and be sure to visit their poster displays in the ballroom to learn more about each innovative venture.

Attendees can also explore the tech hubs and service providers that bring collaborative and mission-driven energy to the RESI community. Connect with these organizations to learn how they support early-stage companies in their fundraising efforts and beyond. Gain valuable insights from these players through educational sessions and exhibits and leverage the dynamic networking receptions to discover exciting new ways RESI can make strategic partnerships for you.

LSN extends its gratitude to our RESI Title Sponsors, BioCat and Biotech Gate, Gold Sponsors, Medmarc and McDermott Will & Emery, and Silver Sponsor, YVC Collective. We look forward to facilitating meaningful connections between these powerful players and the innovators at RESI.


Above all, RESI is designed to connect early-stage companies with capital, licensing, and channel partners that align with their product and stage of development – primarily through partnering. RESI's global partnering platform helps buyers and sellers connect based on various criteria, enabling well-fitting meetings. Life Science Nation invites you to explore the possibilities available through RESI partnering and make the most of your time at RESI. Partnering occurs in person on Monday, June 17, and continues virtually through Wednesday, June 19.

Dennis Ford

Founder & CEO, Life Science Nation
Creator of RESI Conference Series




HILTON DIAGONAL MAR BARCELONA



SSID: RESI_Europe
PW: resi2024

Ballroom



INNOVATORS' PITCH CHALLENGE COMPANIES

- | | |
|--|-----------------------------|
| 1 Lumiris Spectral Solutions | 22 RemAb Therapeutics |
| 2 Onalabs Inno-Hub | 23 Nema Health |
| 3 Aptadel Therapeutics | 24 DyCare |
| 4 PROSPERA BIOTECH | 25 Flomics |
| 5 Aortyx | 26 Time Is Brain, SL |
| 6 CONNECTA Therapeutics | 27 Myrtill Biotech |
| 7 Pharmacelera | 28 Nano4Imaging |
| 8 Pulmobiotics SL | 29 InterAx Biotech AG |
| 9 Gate2Brain | 30 Oxford Drug Design |
| 10 Debios Diagnostics | 31 Valanx Biotech GmbH |
| 11 ZeCardio Therapeutics | 32 NeoTILa |
| 12 Skilled Skin | 33 JOCAVIO |
| 13 PHYSIO MRI TECH | 34 Curavac |
| 14 Ysotope Theranostics | 35 CIS Biopharma AG |
| 15 Implantsdata Ophthalmic Products GmbH | 36 AbbattiaLabs |
| 16 Breaz | 38 Neurocentrx |
| 17 D-Sight S.L. | 39 CERES BRAIN Therapeutics |
| 18 Fecundis Lab | 40 AATec Medical GmbH |
| 19 Heecap | 41 Evariste |
| 20 Biointaxis | 42 Exploris Health AG |
| 21 Oniria Therapeutics, S.L. | |

EXHIBITORS

- 1 Asphalion
- 2 Barcelona City Hall
- 3 Bio Alabama
- 4 AseBio
- 5 o2h Ventures Limited
- 6 One Nucleus
- 7 Biocat
- 8 & 9 Life Science Nation
- 10 Biotechgate
- 11 Mesoscale (MSD)
- 12 Comser Pharma
- 13 LeanBioPro
- 14 Alira Health
- 15 Kinsy
- 16 Cuatrecasas
- 17 Boyds



EXHIBIT TABLES



Table# 1



Table# 2



Table# 3



Table# 4



Table# 5




Table# 6



Table# 7



Table# 8&9



Table# 10



Table# 11



Table# 12



Table# 13



Table# 14



Table# 15



Table# 16



Table# 17



INNOVATOR'S PITCH POSTERS

lumiris | onalabs)

Easel# 1

optadel
therapeutics

Easel# 3

PROSPERA
BIOTECH

Easel# 4

AORTYX

Easel# 5



Easel# 6

Pharmacelera

Easel# 7

Pulmobiotics

Easel# 8

GATE2BRAIN
Medicines beyond barriers

Easel# 9



DEBIOS
Easel# 10

ZeCardio
Therapeutics

Easel# 11



Easel# 12

PhysioMRI
Magnetic Resonance Imaging

Easel# 13



Easel# 14

IOP
Implandata Ophthalmic Products GmbH

Easel# 15

breaz

Easel# 16



Easel# 17

fecundis
Innovative fertility solutions

Easel# 18

heecap
active breathing

Easel# 19



Easel# 20

ONIRIA
THERAPEUTICS

Easel# 21

RemAb
REMOVING HARMFUL ANTIBODIES

Easel# 22

NEMA Health
PEPTIDE-BASED ONCOLOGICAL SOLUTIONS

Easel# 23

DyCare

Easel# 24

Floxxixics

Easel# 25



timeisbrain

Easel# 26

Myrttil Biotech

Easel# 27



Nano4Imaging
YOUR HEALTH - OUR VISION

Easel# 28

INTERAX

Easel# 29

**OXFORD
DRUG
DESIGN**

Easel# 30

VALANX
BIOTECH

Easel# 31

NeoTila

Easel# 32

JOCAVIO

Easel# 33

CuraVac
Therapeutic Vaccines for Autoimmune Diseases

Easel# 34

ciS BIOPHARMA

Easel# 35



Dosage Done Right

Easel# 36

neurocentrx

Easel# 38



CERES

Easel# 39



Easel# 40



EVARISTE
Easel# 41

EXPLORIS

Easel# 42

AGENDA

7 AM – 8 AM: Breakfast Buffet (Ballroom Foyer)

8 AM - 5 PM: Partnering Forum (Ballroom)

	Investor Panels (1st Floor Meeting Rooms 5+6)	Innovator's Pitch Challenge (IPC)		Investor Panels & Entrepreneur's Workshops (Ballroom)
		Track 1 (1st Floor Meeting Rooms 1+2)	Track 2 (1st Floor Meeting Rooms 3+4)	
9:00 AM - 9:50 AM	SEED FUNDS <i>Investing in the Earliest Stage Technologies</i>	IPC SESSION #1 THERAPEUTICS	IPC SESSION #7 MEDICAL DEVICES	
10:00 AM - 10:50 AM	DIGITAL HEALTH <i>Novel Approaches to Improve Quality of Care</i>	IPC SESSION #2 DIAGNOSTICS	IPC SESSION #8 MEDICAL DEVICES	ONCOLOGY INNOVATION <i>The Search for New Approaches to Diagnosing & Treating Cancer</i>
11:00 AM - 11:50 AM	MEDICAL DEVICES <i>Forward Looking Trends in Medical Device Innovations</i>	IPC SESSION #3 DIGITAL HEALTH	IPC SESSION #9 NOVEL DRUG DISCOVERY PLATFORMS	EARLY STAGE THERAPEUTICS <i>Bringing the Newest Therapies to the Clinic</i>
12:00 PM - 1:00 PM	Lunch Break (Ballroom Foyer)		 Keynote session (Ballroom) CATALONIA ADVANCED THERAPIES ECOSYSTEM: BUILDING EUROPE'S FUTURE IN ATMPs	
1:00 PM - 1:50 PM	 YVC Collective <i>How to Approach VCs</i>	IPC SESSION #4 THERAPEUTICS	IPC SESSION #10 DEVICES & DIAGNOSTICS	 LIFE SCIENCE NATION <i>Connecting Products, Services & Capital</i> IT ALL STARTS WITH YOUR STORY
2:00 PM - 2:50 PM	DIAGNOSTICS <i>Advancements for Personalized Care and Medicine</i>	IPC SESSION #5 THERAPEUTICS	IPC SESSION #11 THERAPEUTICS	TALES FROM THE ROAD <i>Biotech and MedTech Innovators on their Fundraising Journey</i>
3:00 PM - 3:50 PM	CROSS BORDER INVESTMENTS <i>Fostering Partnerships With Global Partners</i>	IPC SESSION #6 THERAPEUTICS		 VENTURE VALUATION <small>GLOBAL VALUATION SERVICES</small> Company Valuation for Fundraising
4:00 PM - 4:50 PM	CORPORATE VC <i>Firms Investing Beyond Financial Return</i>			 LIFE SCIENCE NATION <i>Connecting Products, Services & Capital</i> Global Partnering Campaign Investor Landscape, GTL and CRM/GPC
5:00 - 7:00 PM: Cocktail Reception - Announce IPC Winners (2nd Floor: Pergola)				

SPONSORS & EXHIBITORS

Co-organizers




Gold Sponsors



Silver Sponsor



Exhibitors



Co-organizers:



Table # 7

Biocat is the driving force behind the healthcare innovation ecosystem in Catalonia, working to scale and consolidate the life sciences and healthcare sector, generating social and economic impact, and positioning the BioRegion of Catalonia as an international benchmark. Established in 2006 at the initiative of the Government of Catalonia and the Barcelona City Council, Biocat is a public-private foundation with governance bodies comprising representatives from all stakeholders, both public and private.

biocat.cat



Table # 10

Venture Valuation provides product/asset as well as company valuations in the life sciences industry including biotechnology, medical technology, diagnostic, healthIT and pharma. The company's valuations are used for fundraising/investment, M&A, fund valuations, licensing deals and fairness opinions. Furthermore, the company runs the business development database Biotechgate (www.biotechgate.com) as a subscription service. There are currently over 90'000 assets including 40'000 licensing opportunities, 900'000 clinical trials, 35'000 licensing agreements and over 60,000 company profiles available. The information is provided in collaboration with our partners such as AusBiotech, BIO Deutschland, BioFlorida, BIO Maryland, OBN, Swiss Biotech Association, OneNucleus, Medicon Valley, HollandBIO, Montreal Invivo and many more. Venture Valuation has office in Switzerland (HQ), Ireland, UK, Malaysia, India, USA and Canada.

Gold Sponsors:



For life sciences leaders seeking to clear their path to success, McDermott Will & Emery is an industry-leading law firm offering mission- first business solutions that are equally informed by market intelligence and proven experience. We harness the power of collaboration to bring the right combination of people, skills and knowledge to bear at the right time. Composed of top lawyers with demonstrated strength across intellectual property, FDA regulatory, transactional and litigation law, we're a purpose-built team of thought leaders united by a passion for our work. This makes us uniquely qualified to help you move business initiatives across the finish line when it matters and anticipate what's next. McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,200 lawyers strong with a global footprint, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve. plan.



Created in 1979 by 31 members of AdvaMed, Medmarc's mission is to be the superior provider of liability insurance and related risk management solutions. We support the research and development, manufacturing, and delivery of medical products that save lives and improve the quality of life. From ideas and prototypes to the reality of commercialization and success – We Can Meet Your Changing Needs. Contact us to discuss what insurance coverages are needed for your business plan. Medmarc - Business Development * MedmarcInquiries@medmarc.com * 703-652-1360

Silver Sponsor:



We are a network of emerging life sciences venture capital (VC) players. We create events and meet-ups for other YVCs to promote a closer connection between professionals in the life science VC industry in Europe. Our different events aim to drive career development, and foster collaboration and knowledge exchange. We are now representing over 200 YVCs across Europe! If you are working in life sciences VC in Europe and you want to expand your network, connect or exchange thoughts with other professionals in the industry, feel free to reach out.

Exhibitors:



Table # 14

Alira Health is a global healthcare firm whose mission is to humanize healthcare and life sciences in partnership with patients. From development to medical care, we complement the expertise of our Pharma, Biotech, and MedTech clients with a full spectrum of services across their entire solutions lifecycle, including clinical operations, real-world evidence, and patient-centric technology offerings. Our integrated and multidisciplinary team of over 800 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50 MedTech companies and 75% of the top 50 Pharma companies.



Table # 4

AseBio, the Spanish Bioindustry Association, unites companies, associations, foundations, universities, and research centers in biotechnology. Collaborating with governments and social organizations, AseBio promotes science, environmental sustainability, economic development, and high-value employment. For 25 years, AseBio has driven political and economic changes to advance Spanish biotechnology, enhancing quality of life and economic competitiveness. Committed to innovation, AseBio fosters an inclusive ecosystem to address social and generational challenges. As a member of EuropaBio, AseBio represents the interests of over 1,800 European companies, emphasizing cooperation and network collaboration to achieve its goals.



Table # 17

Established in 2005 by Professor Alan Boyd, Boyds operates in the UK, Ireland, and the US with a team of over 30 experienced consultants. We specialize in developing small molecules, biologics, and cell & gene therapies, focusing on rare diseases. Our services cover preclinical activities to Phase 3 clinical development, including integrated development program management, gap analyses, regulatory strategies, product development support, clinical operations, physician support, regulatory affairs, CMC expertise, medical writing, and fundraising/licensing support. We also offer technical and regulatory due diligence for investors. Consult us to support your pharmaceutical and biotechnology projects. Visit BoydConsultants.com.



Table # 2

Barcelona is a vibrant life sciences hub with a robust pharmaceutical sector and over 1,350 life sciences companies. The city and the surrounding Catalonia region, known as the “BioRegion,” are renowned for their world-class network of health institutions, hospitals, research centers, and a thriving ecosystem of biotech and healthtech startups. This dynamic environment fosters innovation and collaboration, making Barcelona a key player in the global life sciences industry. The BioRegion’s comprehensive infrastructure and supportive community provide a fertile ground for groundbreaking research and development in health and biotechnology.



Table # 3

BIO Alabama is the leading advocate for Alabama’s bioeconomy. We represent the state on a national and international stage, promoting the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience. We represent Alabama’s bio related industries, research scientists, clinicians and business professionals who are working together to foster, develop and support the life sciences in Alabama. BIO Alabama is the state affiliate in Alabama of the Biotechnology Innovation Organization (BIO), the preeminent national association for biotechnology companies. Our mission is to promote biotechnology innovation by creating a favorable scientific, business and legislative environment that will facilitate the growth of emerging and existing companies while attracting new biotechnology opportunities to Alabama and to increase public awareness regarding the potential impact on quality-of-life and the state’s economy.



Table # 12

COMSER provides services to the biopharmaceutical, and biotechnology industries, offering the knowledge of our professionals, as well as contract services of the R&D laboratory to deliver end-to-end integral solutions and shortening product’s time to market. With extensive experience and a high degree of specialization in lyophilization and aseptic processing of pharmaceuticals, the company also provides consulting, validation, training, and freeze-drying services to companies working in a GMP-regulated environment. COMSER, your expert partner for overcoming freeze-drying and aseptic processing challenges.



Table # 16

Cuatrecasas is an international law firm firmly established in Spain, Portugal and Latin America, where it has offices in Chile, Colombia, Mexico and Peru. With a multidisciplinary and diverse team of over 1,900 professionals from 29 nationalities, we cover all areas of business law with a sectoral approach, focusing on all types of business. Cuatrecasas has 27 offices in 13 countries and collaborates closely with leading law firms in other countries to offer a team to meet every client’s needs in every scenario.



Table # 15

Spanish CDMO for Drug Substances and Intermediates in the biopharmaceutical industry. Kinsy has a robust expertise in scaling up medicinal chemistry of New Chemical Entities (NCE) and manufacturing batches at small scales for preclinical and clinical phases.




Table # 13

Leanbio is a market oriented CDMO that develops and manufactures biopharmaceutical products as New biological entities and Biosimilars, applying “Lean bioproduction” through tailored quality by design and ICH compliant approach in order to maximize project success, minimize time to market, costs and risks. Leanbio follows a knowledge-based strategy, applying cutting edge technological platforms and working altogether with customers through the different stages of development across project lifecycle: - Platform development - Specific development - Process characterization - Scale-up - Manufacture
Leanbio covers full value chain of services in the development and manufacture of biotherapeutics from gene to vial.



Table # 11

Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.



Table # 5

o2h discovery is a premier provider of small molecule focused drug discovery services, featuring both biology and chemistry capabilities. o2h can support all the stages of early drug discovery, from biological target validation to hit finding, hit expansion, hit to lead, lead optimization and pre-clinical scale-up. o2h operates from its state-of-the-art research centres in Cambridge, UK and Ahmedabad, India. o2h Discovery is part of the o2h group of companies (o2h) founded in 2003 and employs over 500 staff across different departments (chemistry, biology and ADME). Our Indian base allows us to provide an excellent speed and value compared to companies with operations in the West while our UK base provides experienced medicinal chemistry support and sophisticated cellular biology services. o2h’s business (people, process and infrastructure) has been built and developed to provide a tier one option for managing discovery collaborations.



Table # 6

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.



biocat

Why Barcelona

The BioRegion of Catalonia

One of the fastest growing Life Sciences and Healthcare Hubs in Europe

Check the most relevant innovation indicators in the 2023 **Catalonia Life Sciences and Healthcare Report**



Find investable startups, projects and investors in our matchmaking **Investment Portal**



Dive into the **Catalonia Database Sector Platform** (+1700 companies and research organizations)



www.biocat.cat

biocat

Catalonia Advanced Therapies Ecosystem: Building Europe's Future in ATMPs

June 17, 12:00 PM - 1:00 PM | Hotel Hilton Diagonal Mar - Ballroom



Robert Fabregat
CEO
BIOCAT
(Moderator)



Fina Lladós Canela
Vice President General
Manager Iberia
Amgen



Silvia Martín-Lluesma
Clinical Senior Manager of
Advanced Therapies
**Vall d'Hebron Institute of
Oncology (VHIO)**



Lluís Pareras
Founder and Managing
Partner
Invivo Ventures



Antoni Matilla
Cofounder and Director
Biointaxis



Esteve Trias
Executive Medical Director
**Leitat Technological
Center**



THE VALUATION EXPERTS

- ◆ Company and product valuation
- ◆ For investment, M&A, financing and licensing
- ◆ Independent fairness opinions
- ◆ Specialized in Life Sciences, Biopharma, Medtech

We understand your business
www.venturevaluation.com

FUELING YOUR MISSION.

Your passionate pursuit of progress drives innovation in life sciences and healthcare. We know where you're coming from, but more importantly we can help you get where you're going. Let us help you navigate the legal and regulatory landscape.

VISIT US AT [MWE.COM/LIFESCIENCES](https://www.mwe.com/lifesciences)



**McDermott
Will & Emery**



MEDMARC®
LIFE SCIENCES INSURANCE

Insuring the Life Sciences Industry Since 1979

- Products Liability
- Clinical Trials Liability
- Manufacturers E&O

Phone: 888.633.6272 | Email: MedTechLifeSci@medmarc.com
4795 Meadow Wood Lane | Suite 335 West | Chantilly, VA 20151

LEARN MORE
medmarc.com

RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION

Life Science Nation (LSN) has built a global partnering ecosystem featuring healthcare startups and the capital investors, co-development, and licensing partners who seek them. LSN accelerates the fundraising journey by bridging the gap between early-stage entrepreneurs, capital investors, and licensing partners.

- LSN's GPC Platform and RESI Conference Series are invaluable resources for sourcing partners based on product, stage of development, and allocation requirements. These resources are curated regularly and allow for dynamic matching based on fit.
- This one-of-a-kind partnering ecosystem is unique because it is cross-domain, serving the silos of Drugs, Devices, Diagnostics, and Digital Health (the 4Ds).
- The LSN platform also includes relationships with the service providers, tech hubs, and government agencies that provide the international infrastructure that makes the early-stage life science industry run.
- LSN's partnering platform has three components:
 1. Early-Stage Capital and Licensing Partner data profiles integrated with Salesforce CRM
 2. RESI Partnering Events
 3. Entrepreneurial Education and Roadshow Preparation



Table # 8&9

Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.


The GPC integrates LSN's Investor and Licensing Partner Database and the Salesforce CRM. Subscribing companies receive a vetted Global Target List (GTL) of likely partners garnered through one-on-one interviews with the LSN research team, which can be organized into three tiers of Investor Priority:

- Tier 1: Partner is matched on a specific mandate.
- Tier 2: Partner is matched on an opportunistic mandate seeking compelling technology assets.
- Tier 3: Partner is matched as a potential fit based on past or recent actions. This is where the numbers game comes into play.

Information on these profiles is automatically updated daily, and user outreach and tasks can be tracked intuitively with CRM components, including the following:

- Status of Outreach (Lead, Reviewing Materials, Call/Meeting Scheduled, etc.)
- Materials Sent (Executive Summary, Pitch Deck, etc.)
- Notes (NDA status, DD, and data room)
- Reporting (investor/licensing pipeline)

Life Science Nation's (LSN) publications offer a current dialogue for early-stage (seed to series A), life science, fundraising companies to sharpen the skills needed to create a compelling fundraising campaign. These publications include education on how to increase fundraising and marketing efforts for their organization or affiliated startups, expert interviews, event announcements, and active investor mandates. Subscribe and stay up-to-date with meaningful insight into raising capital in the life science industry.





MEDIA PARTNERS

BIG4BIO

FREE MIND
Non-Dilutive Funding Experts

Bio Partner

eurasanté
Invest for Success

LYONBIOPOLE
AUVERGNE-RHÔNE-ALPES
THE HEALTH INNOVATION NETWORK

lsipr
LIFE SCIENCES INTELLECTUAL
PROPERTY REVIEW

BIOINDUSTRY PARK
SILVANO FUMERO

**BUSINESS REGION
GÖTEBORG**

**XB
CHARABIO**

GENOPOLE

BioRN
Cluster
Management

BIO DEUTSCHLAND

**LifeSciences
British Columbia**

**MED-TECH
WORLD**

hypepotamus

BGI
www.bgi.pt

Want to become a RESI Media Partner? Contact us at Marketing@lifesciencenation.com

Life Science Nation (LSN) Services Overview

GPC *Global
Partnering
Campaign*

RESI *REDEFINING
EARLY STAGE
INVESTMENTS*

**Focus
on
Cures** *ACCELERATOR*

**LIFE SCIENCE NATION
PUBLICATIONS**

**LSN Investor & Licensing
Partner Database
(Server)**

5 Times a Year
*January – RESI JPM
March
June
September – RESI Boston
November*

**Entrepreneur
Education
Classes**

LifeSci *(Daily)*
Startup

**LSN GPC Client
Salesforce App
(Client)**

**1,000+
Participating Attendees**

**Seminars &
Workshops**

NEXT PHASE»
(Weekly)

**2500 – 3500
Partnering Meetings**

Branding & Messaging

TECH HUB MONTHLY
(Monthly)

**Participants from
30+ Countries**

**Sourcing Technology
Assets for Partners**

**THE LIFE SCIENCE
EXECUTIVE'S
FUNDRAISING
MANIFESTO**
by Dennis Ford



**LSN Business
Development Database**

PARTNERING FORUM


JUNE 17: IN-PERSON PARTNERING MEETING
JUNE 18-19: VITURL PARTNERING MEETING

Investor Type	Percentage
Venture Capital	27%
Angel & Family Office	19%
Big Pharma & Medtech	17%
Corporate VC	14%
Others	8%
Endowments/Foundations	6%
Government Organizations	9%

Startup Type	Percentage
Therapeutics	47%
Medical Device	32%
Diagnostics	16%
Digital Health	5%

Service Provider Type	Percentage
Professional Services	39%
CRO/CMO	30%
Non-Profit	18%
Suppliers	8%
Others	5%

Who Meets with Whom at RESI Conferences



RESI provides a partnering forum for all stakeholders in the early stage life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.



INVESTOR PANELS

9:00 - 9:50 AM

1ST FLOOR - MEETING ROOMS 5+6

SEED FUNDS PANEL

Investing in Innovation in the Earliest Stages

Investing in the earliest stages comes with a high risk and a potentially high reward. Whether investing in a therapeutics or digital health company, seed investors have to make difficult decisions with a lot less data than other investors. The panelists will discuss topics such as:

- How much proof-of-concept validation is needed for seed funding
- What increased benefit is needed to mitigate the increased risk
- What is unique in the structure of seed-stage deals (convertible notes vs straight equity)
- Does the early stage of the company lead investors to take a more active role

Many investors prefer to wait for later stages due to the decreased risk of failure. Those investors who are willing to take the risk of seed-stage investment will share their approach and selection criteria when assessing early-stage companies.

10:00 - 10:50 AM

1ST FLOOR - MEETING ROOMS 5+6

DIGITAL HEALTH PANEL

Novel Approaches to Improve Quality of Care

This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, change how care is delivered or managed, and how patients are involved in their own care. Panelists will explore topics related to investing in digital health, including:

- In what kinds of digital health technologies are they interested in investing?
- What metrics and evidence do you look for in a digital health startup?
- How can an early-stage digital health company demonstrate the value of their products?
- What are the main challenges for startups raising capital in this space?

The moderator and panelists will discuss this rapidly evolving field of healthcare investment and will introduce the audience to the key fundraising opportunities and challenges facing digital health entrepreneurs today.

10:00 - 10:50 AM

GROUND FLOOR - BALLROOM

ONCOLOGY INNOVATION PANEL

The Search for New Approaches to Diagnosing & Treating Cancer

This panel is a discussion on topics relevant to investment in current innovations in the oncology space. Topics of discussion can include:

- The technologies/approaches that investors find the most compelling
- Whether platform technologies or single assets are preferred for investment/partnerships
- What criteria do investors use when assessing companies for their portfolio or pipeline

Panelists can discuss the industry-wide changes currently seen, including the advance of personalized medicine and the rise of new therapeutic approaches (CAR-T, oncolytic viruses etc.), and how that is affecting the investing landscape.

11:00 - 11:50 AM
1ST FLOOR - MEETING ROOMS 5+6

MEDICAL DEVICES PANEL

Forward Looking Trends in Medical Device Innovations

Investing in medical devices has become more complex with time. While standard medical devices are still a mainstay, there are an increasing amount of combination devices, software-enabled devices and diagnostic devices that require investors to have expertise in multiple sectors. Panelists may discuss topics such as:

- Areas that are currently popular and expected to grow in 2024
- The benefits vs. risks of devices that cross sectors
- Regulatory hurdles / challenges
- Amount/type of data they want to see before investing

Panelists will discuss how to meet the challenges of raising financing for a new device and advise startups on how to make the investment case for their novel technology. Panelists will also explore what technology areas are of top interest to them and how a startup can make themselves stand out in the crowd.

11:00 - 11:50 AM
GROUND FLOOR - BALLROOM

EARLY STAGE THERAPEUTICS

Bringing the Newest Therapies to the Clinic

This panel aims to bring a diverse group of experts & senior decision making staff from VCs, corporate pharma, and other investor types who focus on biotech/ therapeutics investments together to discuss topics such as:

- The decision-making process
- Current areas of interest and areas of high need
- How companies can better differentiate themselves, especially those in overcrowded indications
- Common mistakes/red flags Recently successful deals and how they were successful

The moderator will guide the discussion through topics including how the investors source and vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.

1:00 - 1:50 PM
1ST FLOOR - MEETING ROOMS 5+6

YVC COLLECTIVE INVESTOR PANEL

How to Approach VCs

First-line VC analysts and associates, who are often the first point of contact for new deals, will explain how venture capital firms operate internally. They will provide an in-depth look at the due diligence process and offer expert advice on the best times and methods to present your business opportunity to maximize your chances of securing investment. Gain valuable insights on capturing a VC's interest and successfully navigating the venture capital landscape.

2:00 - 2:50 PM
1ST FLOOR - MEETING ROOMS 5+6

DIAGNOSTICS PANEL

Advancements for Personalized Care and Medicine

This panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:

- Current areas of interest
- Current challenges in this ecosystem – Navigating the competitive landscape
- Commonly observed red flags
- Successful deals Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors.

Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.

3:00 - 3:50 PM
1ST FLOOR - MEETING ROOMS 5+6

CROSS BORDER INVESTMENTS PANEL

Fostering Partnerships With Global Partners

These days, seeking capital from cross-border investors, pharmaceuticals, and other strategic partners may seem like nothing new. Many groups continue to expand into geographies outside of their headquarters to set up new offices, establishing open innovation departments, etc. How can companies better work with buy-side partners outside of their geographies? This panel will discuss the following topics and more:

- Differences in market and regulatory hurdles
- What do cross-border investors seek in companies outside of their headquarters? How are they similar or different to their viewpoint on domestic companies?
- Will cross-border investment activities continue to increase?
- What are some common mistakes investors see from entrepreneurs, and how can they be avoided?

Panelists will discuss how they have been evaluating cross-border investment opportunities, and what the future holds for cross-border activities in the industry. Panelists will also uncover general topics such as navigating the global market and the regulatory challenges associated with market entry, how to approach investors and strategic groups with a global mindset, and more.

4:00 - 4:50 PM
1ST FLOOR - MEETING ROOMS 5+6

CORPORATE VC PANEL

Firms Investing Beyond Financial Return

Corporate venture capital firms are an important source of capital for early-stage companies. Many major pharmaceuticals and large corporations have set up a corporate investment arm to identify early-stage companies. Strategically and financially driven in varying degrees, the implications of working with CVCs are huge, as the resources, network, and guidance provided by the CVC and the associated parent company are incredibly valuable to an entrepreneur who is actively growing their business.

This panel will discuss the following topics and more:

- How are CVCs different from traditional VCs?
- How strategically vs. financially are CVCs driven, and how does this affect their decision-making process?
- How closely does the CVC communicate with the parent company?
- What does working with a CVC entail?

Investor panelists will discuss each of their investment mandates and how they relate to corporate interests, and how they source opportunities. Panelists may also explore current trending areas of interest, and what they see as emerging fields in the near future.

INVESTOR PANEL SPEAKERS



Farzad Abdi-Dezfuli
Partner
Sarsia
Seed Funds Panel

As one of the founders of Sarsia, and the principal analyst regarding life science investments, Farzad brings nearly 30 years of drug development expertise and management from large global pharma and early-stage start-ups. Farzad's experience spans multiple national and global preclinical and clinical drug development initiatives at both administrative and Board levels. In addition to receiving training in entrepreneurial business financing from London Business School, Farzad obtained his doctoral education in pharmacology from the University of Edinburgh Medical School, UK and postdoctoral training from Haukeland University Hospital Bergen, Norway.



Anna Bellmunt
Associate
Asabys Partners
**Early Stage
Therapeutics Panel**
**YVC Collective
Investor Panel**

Anna is an Associate at Asabys, responsible for sourcing and assessing opportunities. Previously, she was an Investment Analyst at LSP, handling deal flow screening and due diligence. She also served as Innovation Manager at Hospital Clínic de Barcelona's Knowledge and Technology Transfer Office, advising on IP protection and commercialization. Earlier, she researched at IRB Barcelona. Anna holds a PhD in Biomedicine from the University of Barcelona, a master's in Biomedical Research from Pompeu Fabra University, and bachelor's degrees in Chemistry and Biochemistry from the University of Barcelona, with research experience in Paris and Barcelona.



Christian Bjelland
Managing Director,
Capital Network &
Global Development
Redesign Health
Digital Health Panel

Christian is the Managing Director of Capital Network & Global Development at Redesign Health, which has built over 65 healthcare startups. Previously, he was a founding GP and Head of Business Development at Trident, and helped found Hello Alfred, leading its growth to over 100 employees. He also worked in Lazard's Power, Energy, and Infrastructure Investment Banking group on M&A and restructuring transactions. Christian holds an AB from Harvard College and an MBA from Harvard Business School. He is a member of the Milken Young Leaders Circle and serves on the International Committee at MoMA.



Jorge Blasco
Venture Partner
(Spain)
Lumo Labs
Seed Funds Panel

Jorge is a serial entrepreneur and investor, known for creating Boutique Secret, a digital e-commerce marketplace sold to Bertelsmann media group. He has invested in over 20 high-tech companies as a Business Angel and advises on fundraising and M&A through The Net Street. As a Venture Partner at LUMO LABS, he focuses on tech investments that improve quality of life and alleviate healthcare and social welfare strains. Jorge holds an Engineering degree from UPC and an MBA from ESADE, where he also teaches. He is the author of an Insurtech book for startup entrepreneurs and managers.



Jeroen Blokhuis

Academic Innovations,
BD and Partnerships

General Inception

**Cross Border
Investments Panel**

Jeroen Blokhuis leads academic innovation, BD & VC partnerships for General Inception in Europe. He holds a PhD in comparative immunogenetics and completed a postdoctoral fellowship at Stanford University. Jeroen co-founded Biotech Connection Bay Area and co-chaired the biotech/pharma investment committee at Life Science Angels. At the Parker Institute for Cancer Immunotherapy, he led business development, established collaborations, managed over 100 patents, and invested in startups now valued at over \$1.5 billion. Returning to the Netherlands in 2019, he served as CBO at Pivot Park and CEO of LungHealth before joining General Inception in 2022.



Salvatore Cappadona

Senior Associate

Criteria Bio Ventures

**Early Stage
Therapeutics Panel**

Salvatore Cappadona is a Senior Associate at Criteria Bio Ventures (CBV), evaluating investment opportunities in Biotech and MedTech. He serves as a board observer for two portfolio companies. Previously, he was a Business Development Manager at the Centre for Genomic Regulation in Barcelona. Salvatore holds degrees in Biomedical Engineering from Politecnico di Milano and Bioinformatics from Chalmers University of Technology, and a Ph.D. in Bioengineering from Politecnico di Milano. He also received executive education in science management from IE Business School, Madrid.



Alejo Chorny

Operating Partner

AdBio partners

**Early Stage
Therapeutics Panel**

Alejo joined AdBio Partners in 2021 as Operating Partner and Head of New Spanish Operations. He began his career in 2018 with Celdara Medical in New York, identifying early-stage assets for licensing. From 2019-2020, he sourced external technologies for BIAL Pharmaceutical, playing a key role in acquiring Lysosomal Therapeutics. Since 2021, Alejo has been COO of Ribonex, developing new oncology therapies. With over 14 years in research on immune-mediated diseases, he has co-authored 35+ publications and filed two patents. He was a senior editor at the Journal of Experimental Medicine and conducted postdoctoral research at the Icahn School of Medicine. Alejo also taught at the School of Medicine at City University, New York.



David Cole

Venture Partner

Springhood Ventures

Digital Health Panel

David is an independent strategic advisor, venture partner, consultant, mentor, social entrepreneur, director, keynotespeaker and podcaster. Specialising in children's health innovation, digital health transformation, strategic growth, and commercialisation. His portfolio of activities includes advisory roles with some of the top children's hospitals across the UK, children's health start-ups, venture capital and accelerator programs. David is also the host of the Not Mini Adults Podcast. David has extensive experience building, leading and motivating teams over a 24+ year career with IBM. He is a skilled technologist, senior business leader, strategist, and creative thinker. As Co-Founder of UK children's charity Thinking of Oscar, David is dedicated to creating fundamental change in how children's health is focused upon and funded. The mission of Thinking of Oscar is 'to bring the future of healthcare to children'.



Fabrizio Conicella
 Head COI&C, Center
 of Open Innovation &
 Competence
Chiesi
**Early Stage
 Therapeutics Panel**

Fabrizio Conicella is the Head of the Center of Open Innovation & Competence (COI&C) at Chiesi. With over 20 years of experience in the biotech and healthcare sectors, he excels in fostering innovation and strategic growth. Fabrizio holds a degree in Business Administration from the University of Turin and has extensive expertise in technology transfer and intellectual property management. He is dedicated to transforming scientific research into viable business opportunities and driving the development and market expansion of biotech innovations.



Joana Correia
 Analyst
Aliath
**YVC Collective
 Investor Panel**

Prior to joining Aliath Bioventures, Joana was an Investment Fellow at Ysios Capital. Joana's past professional experiences also include supporting a clinical research study in prenatal maternal health (immunology) and work as a HCPC registered biomedical scientist for the NHS (diagnostics). Joana has a PhD in Bioengineering from Imperial College London and a master's degree in Nanotechnology and Regenerative Medicine from University College London. Both research degrees focused on the development of non-viral delivery systems for oncology.



Armando Cuesta
 Founding Partner
Korion Life Sciences
**Cross Border
 Investments Panel**

Dr. Armando Cuesta is a Founding Partner at Korion Life Sciences and a Board Member at Eland Private Equity in Madrid. He leads Korion's investment team, focusing on bridging the US and European life sciences ecosystems. Dr. Cuesta advises on program and pipeline strategy for Korion's portfolio companies. He is also a Board Member at Nanobots Therapeutics and Co-founder of Praetorian Bio. Dr. Cuesta earned his MD from the University Complutense and completed a Postdoctoral Fellowship at the Icahn School of Medicine. He is pursuing an Executive MBA at Cornell University and is a New York Academy of Medicine member.



Francesc Dosrius
 Analyst
AdBio partners
**YVC Collective
 Investor Panel**

Francesc worked at the University of Barcelona's tech transfer office, Fundació Bosch i Gimpera, as project manager working on valorization, licensing and business creation, providing support to many spin-offs of the Spanish ecosystem. He is also chief business officer at the Associació de Biocènòlegs de Catalunya, the Catalunya biotech association.



Jordi Ferrer

Healthcare Investment
Director

Ship2B Ventures

Digital Health Panel

With over 12 years of global experience in healthcare, Jordi is passionate about value-based care and how technology can significantly improve access to care as well as people's quality of life. Jordi currently leads healthcare investments at Ship2B Ventures, a European Venture Capital firm investing in early-stage startups targeting Ageing and Chronic conditions, throughout the care cycle. Jordi also acts as Board Director in several portfolio companies and is deeply connected to the European ecosystem through various collaborations with healthcare hubs.



Emma Gasol

Investment Director

AdBio partners

Seed Funds Panel

Emma joined AdBio in October 2023, bringing over 20 years of experience in pharma and biotech. She has led business development and external innovation management, driving initiatives for pipeline generation, portfolio enhancement, and strategic growth. Emma has a proven track record in transactions from early development to commercial stage, including in-licensing and product acquisitions. Starting her career at Crystax Pharmaceuticals in structure-based drug discovery, she then led Corporate Development at Gebro Pharma and was Director of Innovation Scouting at Grifols. Emma is passionate about the transformative potential of early-stage investments in new technologies and therapies.



Tom Gibbs

Senior Investment
Director

**Debiopharm
Innovation Fund**

Digital Health Panel

Corporate VCPanel

Tom is the Senior Investment Director at Debiopharm Innovation Fund in Switzerland, focusing on digital health companies transforming drug development and patient care. He leverages extensive experience to help start-ups build value and make a significant medical impact. Tom serves on the boards of Nucleai, Carevive, BC Platforms, and Immunexpress. His previous board positions include Acteon, Biocartis, and GenePOC. With a background in commercializing life science technologies across start-ups and established companies in Europe and the USA, his expertise spans operations, late-stage product development, marketing, business development, and investment.



Ignasi Heras

General Partner

CRB Inverbio

Digital Health Panel

Ignasi Heras is an accomplished life sciences executive and investor, currently serving as the General Partner at CRB Inverbio. With a focus on venture capital, strategic planning, and corporate finance, Ignasi is dedicated to fostering innovation within the life sciences sector. He is passionate about advancing cutting-edge technologies and therapies that enhance patient outcomes and contribute to the growth and development of the industry. His expertise and leadership drive significant progress in the field, making him a key figure in the advancement of innovative healthcare solutions.



Carsten Laue
Managing Partner
M2Care
Digital Health Panel

Carsten is an experienced entrepreneur and Managing Partner at M2care Venture Studio, where he leads strategic initiatives and drives innovation in the healthcare sector. With many years of experience as CEO and board member, Carsten has a proven track record in developing successful healthcare startups. His expertise includes strategic management, customer value analysis, fundraising and M&A, with a focus on delivering impactful results. In addition, Carsten is an expert in life sciences and digital health at the Swiss innovation promotion agency Innosuisse.



Sarah Luppino
Associate
M Ventures
Corporate VC Panel

Sarah Luppino is an Investor at M Ventures, the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany. She leads the team's efforts on sustainability investments, while also investing in frontier tech and semiconductors. She earned her Ph.D. from MIT in chemistry and has previously worked in business strategy consulting as well as in startups in the nanotechnology and energy & sustainability sectors.



Bill Marks
General Partner & Co-
Founder
**Nexus NeuroTech
Ventures**
**Medical Devices
Panel**

Dr. Marks is the Chief Medical Officer and Co-Founder of Nexus NeuroTech, an investment firm advancing technologies for brain disorders. He is also Adjunct Clinical Professor of Neurology & Neurological Sciences at Stanford University. Dr. Marks earned his MD from Johns Hopkins University and completed his neurology residency and fellowship at UCSF. He holds a Master's in Health Care Management from Harvard. Board Certified in Neurology and Clinical Neurophysiology, his interests include movement disorders, epilepsy, and health technology. Formerly, he was Head of Clinical Science at Verily Life Sciences and now serves as an advisor in neurology for Verily.



Amine Marouf
Principal, Diagnostics
Fund
Kurma Partners
Diagnostics Panel

MSc in genetics (Paris 7 university), and MS from ESSEC Business School. Amine previously worked in the project and portfolio management team at Roche Pharma. He then worked for 5 years as a strategy consultant for innovative companies in the Life Science market. He joined Kurma as an associate in June 2017.



Kerstin Papenfuss
Director, Pharma
**Deep Science
Ventures**
**Early Stage
Therapeutics Panel**

Kerstin started her PhD at German Cancer Research Centre and then moved to a lab at Imperial College to work on novel treatment options within the field of tumour immunology. She since has spent almost ten years in leadership roles at impact-driven organisations advancing medicine and therapeutics, while also securing an executive MBA and a women in business award. Before joining DSV to develop science companies designing more effective personalised therapies, Kerstin was transforming ideas for cutting edge cell and gene therapies into investable propositions at UK's Cell and Gene Therapy Catapult.



Soyoung Park
Venture Partner (US &
Europe)
VU Venture Partners
Seed Funds Panel

Soyoung has a passion for benefiting people with advanced medical technologies. She has invested in various areas under the arm of Health Ageing, focused on digital health, health tech, and biotech for +4 years. Previously, Soyoung spent nearly 15 years in MedTech and biotech, achieving four times 3x-5x exits in the SF Bay Area. Soyoung holds an MBA from the Fuqua School of Business at Duke University.



Laia Pascual
Investment Manager
Ship2B Ventures
**Early Stage
Therapeutics Panel**

Laia is an Investment Manager at Ship2B Ventures' healthcare vertical, focusing on early-stage investments that improve the quality of life of people suffering from debilitating chronic diseases. Her background combines a PhD in Immunology and an Executive MBA. She has 10 years of experience in the startup ecosystem, as an entrepreneur and investor.



Anshal Purohit
Founder and Managing
Partner
Purohit Ventures
Diagnostics Panel

Anshal has over 25 years of experience in healthcare strategy and commercialization. She co-founded Polaris Management Partners (now part of IQVIA) and held positions at Bristol Myers Squibb and Pfizer. Currently, she is the CEO of Purohit Navigation, where she has driven commercial success for over 15 early-stage diagnostic and medical device exits. In 2020, Anshal founded Purohit Ventures, a behavior-based venture fund focused on life sciences. Her passion for innovation helps her spot and support early-stage companies. Honored in the 2021 PharmaVoice 100, she holds an MBA from Columbia University and is a recognized thought leader featured in MedAd News, MM&M, PharmaVoice, and PM360.



Laura Rodriguez

Partner

Invivo Partners

**Oncology Innovation
Panel**

Partner at Invivo Partners, a venture capital firm specializing in early-stage biotech companies. Member of the Board of Directors at OneChain and Telomere Therapeutics and Observer at Arthex, Pulmobiotics, Gyala Therapeutics, Telum, and Esobiotech. Previously a Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona. 5 years of R&D experience in oncology and gene therapy, leading to publications in peer-reviewed journals and collaborations with biotechnology companies. BSc in Biotechnology (Autonomous University of Barcelona, UAB), PhD in Biotechnology (University of Barcelona, UB) with a Postgraduate course in Innovation Management (UAB).



Ruben Sebastian-Perez

Senior Associate

Criteria Bio Ventures

**Oncology Innovation
Panel**

Ruben Sebastian is a Senior Associate at Criteria Bio Ventures, specializing in building and investing in biotech companies. He is a Board Director of a stealth cancer immunology company and a Board Observer of Aboleris Pharma. Previously, Ruben was a Technology and Business Development Fellow at the Centre for Genomic Regulation (CRG), advising on R&D, IP protection, and commercialization. He has also provided due diligence support to early-stage investment firms. Ruben holds a Ph.D. in Biomedicine from CRG and a master's degree in Cancer Biology from the University of Barcelona, with expertise in genome organization, epigenetics, and cell therapies.



Sara Secall

Partner

**Inveready Asset
Management**

Seed Funds Panel

Sara is responsible for building a portfolio of exciting biomedical and health companies at Inveready. She has launched and financed over 25 technology-based companies, and successfully exited several projects with strong VC returns. Since 2001, she has worked in venture capital both in Silicon Valley and in Spain, with technology transfer offices at various universities, and served as an independent expert for the European Commission. She has also consulted in environmental sciences for both Dames and Moore (now URS Corp), the International Finance Corporation, and the World Bank in the US, Canada and Latin America. Sara received her MBA at London Business School, and holds a Master in Sciences from Indiana University Bloomington and a Bachelor of Science in Chemistry from the Universitat de Barcelona.



Gemma Sturt

Senior Investment
Manager

We Venture Capital

Diagnostics Panel

Gemma is a VC Investor at We Venture Capital, the corporate VC arm of Werfen, focusing on disruptive companies in diagnostics and digital health. With over 5 years of experience building and investing in life sciences start-ups, she has supported the deployment of several early-stage VC funds, including at BioCity. Before her investment career, Gemma held commercial roles at two VC-backed start-ups. She graduated in Analytical Chemistry from the University of Manchester and Università degli Studi di Firenze. Gemma is dedicated to advancing innovation in the life sciences sector through strategic investments.



Jose Terencio

Vice President

GRIFOLS

Corporate VC Panel

VP of Grifols Innovation and New Technologies (GIANT), the external innovation arm of Grifols, and CEO of Araclon Biotech. With over 25 years of experience in the pharma and biotech industries, he has held various positions in R&D, innovation, and corporate venture capital. A biochemist by training, he holds a Master's in Drug R&D from the University of Navarra, a PhD in Biology from the University of Barcelona, a Development Management Program (PDD) from IESE Business School, and a Master's in Financial and Accountability Management from Pompeu Fabra University in Barcelona.



Neil Thomas

Chief Business Officer

Cube Labs SpA

**Cross Border
Investments Panel**

Neil is the Chief Business Officer at Cube Labs S.p.A., a venture builder founded in 2013 and headquartered in Milan, Italy. Cube Labs, listed on Euronext Growth Milan since 2023, focuses on building innovative life science companies, with a portfolio of 15 startups and 52 patents. Neil is also a Partner at Ventac Partners since 2012, where he has helped launch over 15 portfolio companies, raised over 1Bn EUR, and facilitated several IPOs. Additionally, he serves as CBO at EOLO Pharma, a spin-out from the Institut Pasteur de Montevideo, Uruguay, developing novel small molecules for cardiometabolic, neurodegenerative, and autoimmune disorders. Neil's extensive experience spans across the USA, Europe, Japan, and China.



Benjamin Torrero

Associate, Head of
Health Investments

**Boost Capital
Partners**

Diagnostics Panel

Benjamin Torrero is a VC investor at Boost Capital Partners, where he invests in early stage companies applying game mechanics to different sectors and verticals within Europe, LATAM and the US focusing on health. Born and raised in Mexico, he started and led an angel syndicate investing in LATAM startups before moving to London.



Ines Ullmo

Associate

**The Venture
Collective**

**Oncology Innovation
Panel**

As a PhD graduate in Cancer Immunotherapy and Immunology from Imperial College London, Ines focused on developing Natural Killer cells from stem cells for cancer therapy. Leveraging this scientific background, she transitioned into the business side of biotech. While finishing her PhD, Ines began working for NK:IO, an Imperial College spin-out commercializing NK cell therapies. At NK:IO, she oversaw investor relations, partnerships, and PR within the UK techbio ecosystem. Alongside this operational role, Ines also started her journey in Venture by joining BlueYard Capital as a Venture Fellow. She then transitioned to become an Associate at The Venture Collective, where she oversees deeptech and biotech investment opportunities with a strong focus on human health and sustainability.



Louise Warme

Head of We Venture
Capital

We Venture Capital
Corporate VC Panel

Louise is the Head of We Venture Capital, with 10+ years of experience in investments in Life Science and board engagements. She has a background as a medical doctor and researcher, and is founding CEO of a medtech startup. Louise also holds a Clinical Innovations Fellowship at Karolinska Institute & Royal Institute of Technology, Stockholm, Sweden. In addition, Louise serves as a director on the board of Axithra and Capitainer and an observer to the board of Deepull and Zetta, our portfolio companies.



Eli Yered

CFO

Sanara Ventures

Cross Border
Investments Panel

Eli brings over 15 years of experience in corporate finance, strategy, and accounting management, underpinned by his background in computer engineering and mathematics. As CFO of PPS, a leading tactile sensing solutions provider, he secured private investments and strategic grants, and facilitated the \$35M sale of Sierra Scientific Instruments. Eli has also advised NGT3, an early-stage investment firm in medical devices and life sciences, and worked at Wells Fargo on M&A and leveraged buyouts. An IDF Officer (reserve duty), Eli holds an MBA from UCLA Anderson and a BSc in Computer Engineering from The Hebrew University.



Nadin Youssef

Senior Analyst

Nina Capital

Medical Devices
Panel

As a highly motivated bioengineer and entrepreneur Nadin has specialised in the creation of start-ups offering medical devices and innovative healthcare technologies. Throughout her career she has learned the ins and outs of advancing innovative technologies including; investment and funding, business modelling, pitching, market access, medical device regulation, computational methods and statistics, biomechanical engineering and design. Today, she's part of the investment team at Nina Capital.



Jaromir Zahradka

CEO & Managing
Partner, i&i Biotech
Fund

i&i Bio

Seed Funds Panel

Jaromir is the co-founder and Chairman of the Board of Directors at i&i Prague, a Bio-Innovation Centre and incubator. He is also the founder and Managing Partner of the i&i Biotech Fund, an early-phase investment fund with over €45 million under management. The fund focuses on European life sciences start-ups with global potential. With 10 years of experience in technology transfer and investment, Jaromir has supported or invested in over 15 biotech spin-offs. He holds a Ph.D. in Biochemistry from Charles University and a master's in Corporate Economics from the University of Economics in Prague. His expertise bridges scientific innovation and business strategy.



Raj Airey

Founding Partner &
Investment Committee
Member

**Convergence
Partners AG**

**Cross Border
Investments Panel**

Raj has been in healthcare for 30 years, of which he spent 20 years in MD roles at Pfizer and Baxter in Europe and Asia. He is also a serial entrepreneur, having built and managed 3 high growth businesses. In the last years, Raj has been an active business angel and company builder in the HealthTech space. He is also an Accredited Executive Coach and mentor and member of the expert advisory board of EIT Health, a pan-European public private initiative that fosters innovation with in healthcare with EU, top universities, innovation hubs and large corporates. Raj is a graduate in science from the London University and has received executive education from both Harvard Business School and INSEAD.



Cinta Díez

Analyst

Invivo Partners

**YVC Collective
Investor Panel**

Bachelor in Biotechnology (URV), Bachelor in Biochemistry (UAB), MSc in Biomedical Research (UPF), PhD in Biomedical Sciences (University of Strathclyde, UK) and MSc in Global Health and Cooperation (UAB). Her research interests and expertise range from neuroscience and molecular biology, focusing on neurodegeneration, nanotechnology and infectious diseases or women's health. She worked as a Postdoctoral Researcher at the Universitätsklinikum Hamburg-Eppendorf (Germany), and later as Technology Transfer Manager at the Universitat Pompeu Fabra's (UPF) Business Shuttle, in Barcelona. Since April 2023, she works as an Investment Analyst at Invivo Ventures, the first fund of Invivo Capital Partners.



Bettina Ernst

Director

BERNINA BioInvest

**Oncology Innovation
Panel**

Bettina has been investing in healthcare companies for the past 6 years. She also serves on the board of several early-stage biotech companies in Switzerland, on the board of the Swiss Biotech Association, and as a member of the advisory board of the Swiss Entrepreneur Fund and of the Innovation Council of Innosuisse. Bettina is a co-founder of two biotech companies. Prior to her investment and entrepreneurial activities, she worked for 10 years in fundamental immunology in the US (Scripps Research Institute, San Diego, CA) and in Europe. Bettina holds a PhD in immunology and an undergraduate degree in natural science from the Federal Institute of Technology (ETH) in Zurich. Bettina resides in Switzerland.



Marc Ramis

Managing Partner

Montana

**Oncology Innovation
Panel**

Marc is dedicated to investing in and building companies in Children's Health and Pediatric Innovation. He is Managing Partner at Montana Impact Fund and Venture Partner at Ship2B Ventures. Marc co-founded and led Rejuveron Senescence Therapeutics AG, Ninevah Therapeutics Ltd, and Senolytic Therapeutics Inc. He is a board member or advisor at Aptadel Therapeutics, Retinset Therapeutics, Gate2Brain, Dive Medical, Oniria Therapeutics, Nanobots Therapeutics, Cebiotex, Cyclomed, and GeneTether. Additionally, he is a Venture Partner at Korion Life Sciences and co-founder of Chasing Science and Manor House. Marc has significant experience in the biotech and medtech sectors.

Find More Investor Panel Speakers on RESIConference.com

9:00 AM - 3:50 PM | INNOVATOR'S PITCH CHALLENGE (IPC) TRACK 1

Location: Meeting Rooms 1+2 (1st Floor)

Pitch Company

9:00 - 9:50 AM

IPC SESSION #1 CLINICAL STAGE THERAPEUTICS



Easel# 17



Easel# 22



Easel# 34



Easel# 38

10:00 - 10:50 AM

IPC SESSION #2 DIAGNOSTICS



Easel# 10



Easel# 14



Easel# 25

11:00 - 11:50 AM

IPC SESSION #3 DIGITAL HEALTH



Easel# 12



Easel# 24



Easel# 32



Easel# 42

1:00 - 1:50 PM

IPC SESSION #4 THERAPEUTICS



Easel# 3



Easel# 23



Easel# 35



Easel# 41

2:00 - 2:50 PM

IPC SESSION #5 THERAPEUTICS



Easel# 6



Easel# 9



Easel# 20



Easel# 39

3:00 - 3:50 PM

IPC SESSION #6 THERAPEUTICS



Easel# 8



Easel# 21



Easel# 30



Easel# 33



Easel# 17

D-Sight is a spin-off company from Vall d'Hebron Institute of Research developing a first-in-class eye drop solution for the early treatment of diabetic retinopathy (DR). This is the most common neurovascular complication of diabetes and the leading cause of preventable blindness in working-age population worldwide. There are currently no treatments for DR on its early stages. The only available therapies are focused on more advanced stages of the disease, are invasive and present severe adverse effects for the patients. D-Sight is offering a non-invasive, safe and cost-effective solution for a global unmet medical need. The company has already completed the preclinical regulatory studies for its treatment and will initiate a phase I clinical trial by Q1 2025. D-Sight has already closed a seed round of 1m€ with Clave Capital, and it's currently fundraising for a pre-series A round of 3m€.



Easel# 22

RemAb Therapeutics (RemAb) is an already clinical biopharmaceutical company. RemAb is developing a novel class of polymeric medicinal products to selectively remove specific harmful antibodies in different contexts and pathological conditions mediated by such antibodies, including autoimmune - allergic diseases, infectious diseases, ABO incompatibility in solid organ and cell transplantation, and modulation of the humoral immune response against viral vectors to improve safety and efficacy of gene therapy.



Easel# 34

CuraVac is a clinical-stage biotech company developing Therapeutic Vaccines for autoimmune diseases. Thanks to a revolutionary new technique based on reverse mRNA sequences and complementary peptide antigens, CuraVac aims to induce long-term immunity against autoimmune diseases such as Myasthenia Gravis (MG), MS, T1 Diabetes, SLE or Hashimoto's disease. CuraVac Therapeutic Vaccine for MG called CV-MG that demonstrated an excellent safety profile and indicate efficacy in a phase 1 on patients and is preparing a demonstration of efficacy of an improved formulation.



Easel# 38

Neurocentrx is seeking the 1st FDA approval of a "safety-first" abuse-deterrent oral ketamine for severe depression. The company is conducting Phase 2 proof-of-concept studies, to demonstrate efficacy and safety of a novel ketamine formulation and digital prescription care safety platform across both clinical and home treatment settings. Our pipeline includes multiple Ph2 studies in treatment-resistant major depression, bipolar depression and severe anorexia. We are seeking investment and strategic partners to develop our programme towards market approval in under 4 years. We work with leading psychiatrists in London and Boston and have received funding support from the Wellcome Trust and UK Medical Research Council.



DEBIOS
Easel# 10

DEBIOS is a spin-off from the Institut Germans Trias i Pujol (IGTP), established in 2023, focused on developing innovative diagnostic technologies for early identification of genitourinary diseases. The company aims to commercialize FIBROKIT, the first IVD device for non-invasive early diagnosis and continuous monitoring of renal fibrosis in patients with chronic kidney disease (CKD).



Easel# 14

Ysotope is a pioneering biotechnology company specializing in the development and commercialization of advanced radiopharmaceuticals for precision oncology. Established to leverage cutting-edge research in nuclear medicine, Ysotope focuses on creating innovative diagnostic radiotracers targeting specific cancer biomarkers, such as GD2. These radiotracers are designed to improve the detection, treatment, and monitoring of various cancers, including neuroblastoma and glioblastoma. Ysotope collaborates closely with leading research institutions, such as the Vall d'Hebron Institute of Research (VHIR), to accelerate the translation of scientific discoveries into clinical applications. With a strong emphasis on innovation and patient outcomes, Ysotope aims to enhance the efficacy of cancer treatments and improve the quality of life for patients.

Flomics is developing a liquid biopsy test, dynamic and capable of detecting multiple complex diseases, such as cancer, even before the first symptoms appear. Our blood-test combines proprietary optimized protocols for plasma cell-free RNA (cfRNA) profiling based on Next-generation sequencing (NGS) with state-of-the-art bioinformatics data analysis with machine learning. Flomics proprietary AI classifier is completely implemented in the cloud for faster scaling up. Currently we are working with our clinical partners, such as Hospital Clinic de Barcelona, in demonstrating the capacity of our liquid biopsy to detect cancer warning signs in an accurate, fast and minimally invasive way, before it's too late. Everything out of a standard blood sample.



Easel# 25



Vote for Your Favorite Technology

Conference attendees will be given “RESI Cash” upon entry to invest in the companies they find most compelling throughout the entire 2 days of the in-person RESI. Top 3 companies with the most RESI Cash “invested” are announced during the closing networking reception.

- 1st Place – Complimentary tickets to 3 RESI events of your choice (up to 2 tickets per event)
- 2nd Place – Complimentary tickets to 2 RESI events of your choice (up to 2 tickets per event)
- 3rd Place – Complimentary tickets to 1 RESI event of your choice (up to 2 tickets per event)



Easel# 12

As a company, our goal is to minimize the impact of chronic skin diseases by combining the use of AI with new imaging modalities such as infrared thermography. Specifically, our product allows healthcare organizations to enable less specialized staff to speed up diagnosis, promote prevention through patient engagement, and consequently optimize the high costs associated with these pathologies in terms of both economic and quality of life. In the case of chronic wounds, our goal is to prevent their occurrence and, if they do occur, to prevent their stagnation and to heal them in the shortest possible time. This means increased longevity and quality of life for patients and enormous savings for payers. At derma, our goal is to ensure early diagnosis and offer personalized treatments to avoid anxiety/depression problems for these patients and costs for healthcare systems.



Easel# 24

ReHub by DyCare is a B2B clinically-proven digital platform that revolutionizes the way rehabilitation services are delivered remotely. Through the fusion of cutting-edge computer vision technology and AI algorithms, ReHub empowers individuals to effortlessly access personalized and convenient home rehabilitation programs, all while seamlessly tracking and monitoring their progress. Earning the prestigious CE Mark, ReHub stands as a beacon of credibility and excellence. With over 2 million therapeutic exercises executed and more than 20,000 patients benefiting, its impact spans mainly across Spain, Italy, and South America. Prestigious rehabilitation centers and Hospitals like Vall d'Hebron, Istituto Maugeri, Humanitas, and Hospital Fundación Santa Fe Bogotá, as well as revered Health Insurance Companies including DKV and FIATC, have embraced ReHub's potential.



Easel# 32

NeoTila Pte Ltd is a Singapore-founded stealth clinical stage cell and immunotherapy biotech and digital health startup. We focus on designing a series of precision cell therapy products aimed at arresting inflammation, as adjuvant therapy in liver and colorectal cancer to prevent relapse, and also designing next generation cellular immunotherapies against advanced liver and other gastrointestinal cancers. As a real-time enabler, we developed a bioinformatical datamart to identify potential at-risk patients with liver disease, and providing a potentially powerful data driven and predictive tool for surveillance of fatty disease, liver fibrosis and thereby better detecting and intervening at an early stage of an inflamed liver – now the major risk for liver cancer, the world's third commonest cause of all cancer deaths. The platform is secured, built on blockchain with AI Capabilities.



Easel# 42

Exploris Health provides AI based diagnostics and therapy solutions. Our first product Cardio Explorer allows to diagnose coronary artery disease (main cause of heart attack) from a blood sample with the accuracy of a CT/MRI. Pipeline with further AI-generated multi-marker algorithms in place.



Easel# 3

Aptadel's novel technology involves the creation of a platform based on aptamer-drug conjugates (ApDC), where the aptamer has anti-metastatic properties, serving as a vehicle for targeted delivery of new drugs, and can be customised for different types of tumours expressing the EphA2 receptor. Aptadel's lead asset addresses Ewing sarcoma (ES), a devastating paediatric cancer with high mortality in metastatic patients. Current treatment options, such as chemotherapy, have limited efficacy and high toxicity. Aptadel's ApDC may become a first-line treatment designed for children, being more effective and safer than current options.



Easel# 23

NEMA HEALTH is a preclinical stage company that has been founded as a spin-off of the Universitat de Lleida and the Vall Hebron Research Institute. The company main asset is ONCONEOVAC, a personalized immunotherapy for cancer which is being developed for the treatment of local and metastatic melanoma in advanced phases. ONCONEOVAC's technology is based on the therapeutic effect induced by the patient neoantigens extracted from the tumor when formulated /adjuvanted with a set of proprietary peptides known as DIF peptides. The invention of this set of peptides and their medical uses is protected under a patent application. ONCONEOVAC is proposed as a personalized immunotherapy for those patients with advanced melanoma who are unable to induce an immune response with checkpoint inhibitors or have resistance to targeted therapies. We expect to provide a new tool to oncologists that can contribute to give better alternative treatments to patients.



Easel# 35

CIS Biopharma is a preclinical stage biotech company developing ADCs and radioligands inhouse. The company pioneers new targets and new modalities to make a difference for the lives of cancer patients with aggressive forms of cancer. The executive team has successfully built oncology pipelines for Roche, Merck, Amgen, Pfizer and CIS Pharma. Linker/payload chemistry and bioconjugation is the expertise of the scientists working in the lab. CIS Biopharma develops conjugates specific to tumor target and indication, addressing diseases with a high unmet need. CBO-001 targets L1CAM, a first-in-class, CBO-002 targets B7H3. Both products comprise best-in-class potential for SCLC and GBM respectively, with a wide pan-tumor potential.

EVARISTE
Easel# 41

Evariste is a techbio startup that develops small molecule therapeutics for synthetic lethal oncology indications. We use our mathematical modeling and machine learning platform - Frobenius - to discover novel targets and biomarkers, rapidly generate successful hits for difficult-to-drug targets, and develop those hits into optimized drug candidates.



Easel# 6

CONNECTA Therapeutics is a clinical stage biotech company based in Barcelona developing new treatments for CNS diseases with a strong commitment to orphan and paediatric indications. CONNECTA's leading program is focused on the clinical development of CTH120, a first-in-class neuroplasticity modulator, orally bioavailable, with a clinically validated safety profile and broad therapeutic application. CONNECTA plans to start CTH120's Phase II clinical trial for the treatment of fragile X syndrome (FXS) in the first half of 2025. FXS is the most common cause of hereditary intellectual disability without specific treatments available. CONNECTA is seeking additional funds to extend its CTH120 program to other neurodevelopmental disorders (e.g. Down syndrome and Rett syndrome) and to expand the company's pipeline with the discovery of new clinical candidates to become a leading company in the CNS field.



Easel# 9

Gate2Brain is a technologic platform based on a set of small peptide-shuttles that have the capacity to cross the BBB and carry to the CNS therapeutic cargoes that cannot reach the brain unaided. G2B-002, our flagship product, is a new therapeutic approach to fight against untreatable pediatric-first brain tumors with intact BBB. Gate2Brain novel delivery technology provides a non-invasive, non-antigenic, stable, soluble, and receptor-specific way to transport drugs across the BBB to reach the CNS. Our technology has the potential to be applied in a wide number of therapeutic areas and in transport through various biological barriers. We have demonstrated delivery of any kind of molecule from antibodies and ADCs to small molecules, through nanoparticles and oligos. Gate2Brain is looking to co-develop novel CNS targeting therapies with external partners while, in parallel, developing our internal flagship product in brain tumors.



Easel# 20

Founded in 2018, Biointaxis is an academic spin-off company benefiting from extensive know-how in the identification of genes, biomarkers and mechanisms underlying neurodegenerative disorders. Our leading candidate, BTX-101, is currently a novel gene therapy product for the treatment of Friedreich's Ataxia (FRDA), a rare devastating inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults for whom there are no treatments.



Easel# 39

Ceres Brain Therapeutics is developing CBT101, a unique patented drug that delivers creatine/energy to brain neurons to restore energy homeostasis and ensure neuroprotection. CBT101 is indicated in neurodegenerative diseases with high unmet clinical needs including ALS (40,000 patients; >€1,5B market), Creatine Transporter Deficiency or CTD (rare gene disease leading to severe intellectual deficiency; 16,000 patients; >€1B market) and Parkinson's disease (>10millions patients in 2030; >€10B market). CBT101 led to remarkable proofs of efficacy in animal models increasing brain plasticity, metabolism and cognition while demonstrating neuroprotection. CBT101 is expected to reverse symptoms in children lacking brain creatine, slow down/stop disease progression and improve daily life symptoms in neurodegenerative diseases. Orphan drug designation was granted by EMA/FDA in CTD and regulatory CMC and 2 weeks regulatory tox were conducted. Led by a strong team mixing scientific and business skills, Ceres is raising 6M€ to demonstrate CBT101 efficacy in patients.



Easel# 8

Pulmobiotics is a spin off company from the Centre for Genomic Regulation (Barcelona, Spain) founded in 2020. We started with a seed investment of 2m € from Invivo Capital also raised 4,8m € of non-dilutive funding. We are the first synthetic biology company to design recombinant live biotherapeutic (LBPs) based on human lung bacteria for the treatment of respiratory diseases. We have proprietary synthetic biology tools that allow us to obtain novel biological products based on genetically engineered bacteria (LBPs) that contain all the machinery necessary to synthesize different proteins simultaneously, opening the possibility of generating new combinatorial and local or site-specific therapies with reduced side effects. Using this technology, we are developing a pipeline of products to treat complex respiratory diseases like antibiotic resistant infections, lung cancer, asthma and COPD.



Easel# 21

Oniria Therapeutics is a biopharmaceutical company focused on the field of precision oncology. It develops first-in-class therapies designed to target vulnerabilities of persistent tumor cells as a novel strategy to fight cancer. Our flagship product, ONR-001, is an oral small molecule that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter a dormant state and even die. It is indication agnostic and can be used at all stages of the disease. We have already demonstrated in-vivo efficacy in melanoma, colorectal cancer and acute myeloid leukemia with very good tolerability in rodents. We are currently selecting the Final Candidate.



Easel# 30

Oxford Drug Design is a pre-clinical therapeutics spinout from Oxford University developing first-in-class treatments against cancer and other major diseases. Our distinctive AI drug discovery platform (SynthAI) integrated with leading tRNA synthetase (aaRS) target expertise overcomes inefficiency limitations of current methods and accelerates the potential impact for patients. This differentiated capability has already delivered in vivo proof of concept for a first-in-class treatment in oncology and plans for further efficient discovery of new drugs are in development.



Easel# 33

JOCAVIO aims at EFFICIENT and SAFE gene therapy by combining the advantages of VACCINIA VIRUS, which can carry multiple genes and large gene at once, with our own INNOVATIVE TARGETING technology. We are developing 1) an inflammatory cell-specific targeting system and 2) a oncolytic virus therapy that can be administered systemically. For 1), currently aiming to raise 1M USD with the goal of obtaining a non-clinical POC in 2024 and concluding a license agreement by the end of 2025. For 2), currently aiming to raise 3.4M USD with the goal of obtaining a non-clinical POC and CMC validation in 2024, with the FIH after 2025 and IPO after 2026. We are looking for investor(s) who can support R&D to FIH and strategic partner(s) for development and marketing beyond phase II.

9:00 AM - 2:50 PM | INNOVATOR'S PITCH CHALLENGE (IPC) TRACK 2

Location: Meeting Rooms 3+4 (1st Floor)

Pitch Company

9:00 - 9:50 AM
IPC SESSION #7
MEDICAL DEVICES




10:00 - 10:50 AM
IPC SESSION #8
MEDICAL DEVICES



11:00 - 11:50 AM
IPC SESSION #9
NOVEL DRUG DISCOVERY PLATFORMS



1:00 - 1:50 PM
IPC SESSION #10
DEVICES & DIAGNOSTICS



2:00 - 2:50 PM
IPC SESSION #11
THERAPEUTICS





Implandata Ophthalmic Products GmbH

Easel# 15

Implandata is an ophthalmic digital health/device start-up company headquartered in Germany with 12 employees and having raised €20m in equity until today. We are improving the life of millions glaucoma patients and preserving their eyesight by introducing remote disease care. Our CE marked EYEMATE system is ready for commercial launch in Europe and Breakthrough Device Designation ensures an expedited FDA market authorization process. Our customers are eye centers, prescribing our solution to their glaucoma patients to personalize therapy and more efficiently manage their patients. And to empower patients via self-monitoring. We are currently raising our next funding round to expand into the European and certain Asian markets and to obtain FDA approval for US market launch in 2027.



Easel# 18

Fecundis Lab increases access to fertility treatments through its technological platform that centers the sperm both as a target for treatments and therapeutic vehicle. Fecundis's technology allows for higher success rate, lower time to pregnancy, lower treatment barriers and increased flow of patients through clinics.



Easel# 19

heecap mission is to accelerate respiratory autonomy of patients under mechanical ventilation supports in Intensive Care Units. Every year, 6.3 million patients around the world are on prolonged mechanical ventilation supports, what means suffering from ventilation-induced respiratory muscle atrophy complicating the process of liberation from ventilation. heecap is a classIIa medical device that activates respiratory muscles with non-invasive electrical stimulation in synchronization with patients breathing, from the very beginning of ventilation. heecap vision is to partner with mechanical ventilation industry leaders, manufacturers and distributors, to arrive to ventilated patients around the world.



Easel# 28

Nano4Imaging (N4I) develops software and devices for interventional MRI (iMRI) based on artificial intelligence and nanotechnology. N4I offers three groundbreaking technologies — trackr.software, Magnafy, and EmeryGlide — enabling the use of MRI for endovascular interventions, an alternative to cath lab procedures driven by X-ray imaging. Benefits of iMRI include better soft tissue visualization, no radiation exposure, no need for contrast agents, expanded diagnostic functionality, and a smaller environmental footprint. TAM for iMRI is projected to be \$1.8 billion in 2030. EmeryGlide guide wire received FDA 510(k) clearance. FDA clearance of the new supply chain is expected in Q1/2025. FDA clearance of software is anticipated for 2026. N4I projects strong growth, with revenues increasing from \$0.5 million in 2025 to \$55 million by 2030. N4I has raised \$12.5 million in seed capital. The company is seeking \$10 million in Series A funding, with \$5 million already secured by the EIC.



Easel# 5

Aortyx is a pioneer company that aims at providing a new generation of endovascular devices to treat aortic diseases. With an initial focus on aortic dissection, Aortyx is developing a family of biomimetic, bioresorbable endovascular patches that are deployed via a specialized aortic catheter. The patches are designed to adhere to the vessel wall, and to promote natural repair of the aorta and biointegration within the native tissue. Aortyx' mission is to provide lifesaving solutions for patients with aortic diseases. We aim at delivering specialized tools designed to definitively heal the aorta to cardiovascular surgeons and aortic disease patients. Our goal is to reduce uncertainty, improve patient outcomes, and lower treatment costs in aortic disease care.



Easel# 13

Physio MRI Tech SL (PhysioMRI) is a medical device start-up originating from the Institute of Instrumentation for Molecular Imaging (i3M), a research center by Universitat Politècnica de València (UPV) and Consejo Superior de Investigaciones Científicas (CSIC). Founded to commercialize significant MRI research, the company aims to democratize MRI use with innovative, cost-effective scanners. Collaborating with global institutions like Leiden University, PhysioMRI developed a joint-focused MRI device costing under €50k, significantly cheaper than traditional models. This device is lightweight, easily transportable, and operable via standard electrical outlets, making MRI accessible to primary care centers, small clinics, and sports clubs. This advancement could extend MRI diagnostics to underserved areas globally. The technology is protected by three patents involving pioneering MRI methods and designs. PhysioMRI's founding team, bolstered by new international partners, is committed to transforming the MRI landscape.



Easel# 36

At AbbattiaLabs, our mission is to address the challenges involved in customizing dosages of solid medications. This is particularly crucial for pediatric patients, as well as certain adult treatments, where precise dosing is essential. Our solution is a sustainable prefilled device with a built-in dosing mechanism, enabling users to effortlessly and accurately administer the exact amount of medication. We are now initiating development projects with different pharmaceutical companies who are willing to use our device with their drugs. Therefore, we are seeking funding for the next phase of development (industrialization) and to facilitate our company's growth.





Easel# 7

Pharmacelera is a deep tech company that applies accurate proprietary Quantum-Mechanics (deep physics) and Artificial Intelligence algorithms to mine the exaSpace (billions of molecules), breaking IP barriers 1000x times faster. We are already partnering with big pharmas and biotechs in Europe and the US and we have engaged on a strategic alliance with General Inception, an investor from Silicon Valley. The company will create its first spin-off in the US, a strategic market for the company in 2024.



Easel# 11

ZeCardio Therapeutics (ZeCardioTx) is a biotech company aiming to revolutionize the discovery of new cardiovascular drugs impacting the lives of millions of patients suffering from acute myocardial infarction, genetic heart diseases and heart failure caused by anti-tumoral cardiotoxic side-effects. These diseases represent highly unmet medical needs and huge market opportunities. To this end, ZeCardioTx has developed an innovative target and drug discovery platform combining translatable experimental models – zebrafish and hiPSC – with AI. ZeCardioTx platform can uncover and validate novel therapeutic targets and screen compound libraries in vitro and in vivo to discover drugs with high chances to become new clinical candidates. Our pipeline: CardioReg: a cardiac regenerative small molecule (ZXR-81) aiming to become a first-line treatment to repair/regenerate infarcted hearts and prevent heart failure after infarct. CardioMyo: Development of small molecules (ZMX-6 & 7) to treat Dilated Cardiomyopathy patients. CardioProt: Development of small molecules protecting against chemotherapeutic-induced cardiotoxicity.



Easel# 27

Develop medicines for patients with titinopathy, a genetic form of dilated cardiomyopathy (DCM). Utilizing our human disease models, novel AI, and the best-in-world platform, we are the leading partner in guiding the path from target discovery to clinical realization.



Easel# 29

InterAx has developed a unique drug discovery platform integrating biochemistry and AI to decode the cellular communication language, which is crucial to develop treatments for unmet medical needs in cardiovascular, cancer or neurological diseases. InterAx has discovered a potential best-in-class GLP1 agonist exhibiting comparable efficacy and tolerability to the current leading diabetes treatments. Testing has already been conducted on a GIP-R compound. Considering this, a combination of GLP1/GIP acting compounds appears to be the most promising approach for developing a best-in-class treatment for obesity. The target product profiles of the 2 products are i) an oral once daily sustained release capsule with improved tolerability to reduce nausea with the potential for earlier stage of disease intervention to delay progression of T2D and potentially for weight management, and ii) orally available co-formulated dual GLP1/GIP drugs for T2D and for long term weight management. We aim for 2 IND filed in 2025.




Easel# 1

Lumiris' goal is to help intended parents undergoing in vitro fertilization treatments achieve a pregnancy faster by selecting the most competent embryo. We introduce a novel hyperspectral technology to help professionals evaluate embryos reducing subjectivity. This non-invasive technology offers new and more accurate color-coded images to observe embryo metabolism compared to the current standard which provides only black and white images of embryo morphology.



Easel# 2

In Onalabs we have developed a new digital biomarkers platform that decode information from your sweat & skin to monitor your health. Onalabs patented technology is based on non-invasive sensors for remote and real-time monitoring biochemical biomarkers through the sweat. Getting big quantity of internal body data to manage artificial intelligence to achieve precision and personalized medicine.



Easel# 16

BREAZ Medical SL is a Barcelona-based MedTech startup simplifying lung health diagnostics. They are developing a novel solution for accessible diagnosis and monitoring of chronic lung diseases in resource-limited settings like primary care with your GP, starting with chronic obstructive pulmonary disease (COPD). By detecting chronic respiratory diseases earlier and improving the accuracy of the diagnosis in community settings, they want to reduce the huge burden of these diseases on society, improve patient quality of life, reduce mortality, and reduce hospitalisations. Their solution is a simple-to-use intelligent hardware tool based on validated sensor technologies combined with novel data interpretation algorithms. It provides an accurate and robust method to help physicians diagnose, monitor and correctly treat their patients.



timeisbrain

Easel# 26

Time is Brain (TiB) is a technology-based startup founded in 2020 by Key Opinion Neurologists from Germans Trias Comprehensive Stroke Center (Barcelona) to change the devastating impact of stroke and other neurological conditions. At TiB, we have created BrainN20®, an innovative medical device for stroke care diagnosis and management. It enables real-time monitoring of the brain's status from the onset of a stroke through the entire patient journey. Classified as a class IIb medical device with a maturity level of TRL7, BrainN20® offers fast recording and automatic analysis of the N20 proprietary biomarker. This technology is designed for comprehensive stroke centers, primary hospitals, and emergency services. It facilitates accurate and rapid referral for Endovascular Thrombectomy (EVT) treatment and continuous monitoring, ensuring standardized, equitable, and improved health outcomes for all acute stroke patients. Our unique, patented technology and unparalleled solutions promise to revolutionize stroke treatment protocols and improve patient outcomes globally.



Easel# 4

Prospera Biotech develops and markets innovative neurodermatology products (a.k.a. Nociceuticals®) directed to improve the quality of life (QoL) of people with sensitive & reactive skin caused by pharma treatments or pathologies. Prospera Biotech innovative solutions protect the peripheral nociceptive nervous system by relieving skin sensory distress such as itching, pain, numbness, and tingling. Currently, Prospera Biotech has 5 Nociceuticals® on the market, an exclusive license for using Calmapsin® to alleviate chemotherapy-induced cutaneous discomfort of cancer patients, an international patent application for hyperhidrosis, and 5 products in development to be marketed in 2025-2026.



Easel# 31

VALANX Biotech has developed a cutting-edge site-specific protein conjugation platform. The first product, VLX101, out of the platform is a novel, fully proprietary Interleukin-2 conjugate with a unique mode of action. First in-vivo trials have shown that VLX101 can fully resolve inflammation in a mouse model and compares very favourably to competitor molecules previously developed. Additionally, our platform enables the development of high-quality Antibody-Drug-Conjugates. for which we have recently signed a tech-evaluation contract with a big pharma partner. We have further brought into development VLX301, which is a novel antibody-fragment drug conjugate positioned to resolve issues of tumour penetrability of traditional ADCs.



Easel# 40

AATec Medical develops a radically new drug platform for airway inflammatory diseases. Our product platform is based on recombinant human AAT (alpha-1 antitrypsin) for pulmonary delivery. AAT has broadband anti-inflammatory properties, inhibiting tissue-damaging neutrophil proteases, modulating inflammatory cytokines, and providing anti-infective effects. We apply our products by inhalation to achieve optimal effects directly in the airways. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization.

ENTREPRENEUR'S WORKSHOPS

1:00 - 1:50 PM
GROUND FLOOR - BALLROOM

IT ALL STARTS WITH YOUR STORY



The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company's unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.



Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. Dennis has spent a decade in the early-stage life science arena creating a partnering platform that matches next-generation drugs, devices, diagnostics, and digital health products with investor and licensing partners. Dennis has developed an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. Dennis has also pioneered a unique global partnering event called the Redefining Early-Stage Investments Conference Series that matches investors and licensing partners with startup firms based on stage of development and product.

Dennis is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, two well-received sales and marketing books. His latest book is *The Life Science Executive's Fundraising Manifesto* which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO which is now offered to help launch and fund startups into the global life science arena.



Greg Mannix, VP of International Business Development, Life Science Nation

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.



Moderator

Greg Mannix, VP of International Business Development, Life Science Nation

Greg Mannix is Vice President of International Business Development at Life Science Nation. A graduate of the University of California, he holds a Master's from IE Business School in Madrid. Greg has extensive sales and marketing experience in both large medical device corporations and start-ups. He has worked across Europe, North America, and Latin America, and speaks English, Spanish, and French. Six years ago, he relocated to Boston to establish the US affiliate for a Spanish Med-tech company. Now at LSN, Greg continues to thrive in the vibrant startup community.




Ana Maiquez, CEO, Neuroelectrics

Ana Maiques is a prominent leader in entrepreneurship and neuroscience, co-founding Neuroelectrics to pioneer brain monitoring and stimulation technologies. Under her leadership, Neuroelectrics was named one of Entrepreneur Magazine's Best Entrepreneurial Companies in 2016. Ana has received numerous accolades, including the Most Exceptional Entrepreneur Award from Goldman Sachs in 2022 and the EU Prize for Women Innovators in 2014. She has been a European Innovation Council Advisory Board member and a Termeer Fellow since 2018. As a co-founder of EsTech, she supports Spanish scale-ups and unicorns. Ana is a passionate advocate for gender equality in STEM, actively creating opportunities for women.



Isabel Portero, Founder & CEO, Biohope

Dr. Isabel Portero, MD, PhD, is the Founder and CEO of BIOHOPE, a startup focused on precision medicine for personalized treatments. With over 15 years of experience in the biomedical field, she has held roles at Merck, Roche, and Cellerix/Tygenics. Dr. Portero's dedication to organ transplantation led to BIOHOPE's founding in 2015. Her work earned a €3.4M European Commission grant and recognition in Forbes' 100 Most Creative People in Business (2018). She is a passionate advocate for patient-focused healthcare and innovation.



Angel Alberich, Founder & CEO, Quibim

Angel Alberich-Bayarri is the CEO and co-founder of Quibim, a global company specializing in advanced medical imaging and AI tools for accurate diagnoses and treatments, particularly in cancer detection and prediction. He is a Telecommunications Engineer from the Polytechnic University of Valencia and holds a Ph.D. in Biomedical Engineering. With 15 years of experience, Angel has a deep understanding of medical imaging and computer vision. He is the inventor of seven patents, has received international awards including MIT Innovators Under 35, and has published over 100 articles. He is also an invited speaker at major international conferences.



Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, it's important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.




Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. He started the company in 1999 when he noticed a need for independent valuation services in high growth industries during a collaboration with Novartis Venture Fund, which became his first client. Since then he has been involved in over 450 valuations for investors as well as biotech, Pharma and medtech companies. Patrik graduated from the Business University of St. Gallen and completed his PhD thesis ("Assessment and valuation of high growth companies") at the Swiss Federal Institute of Technology, EPFL Lausanne. Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical and also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik was member of the board of Aventron AG (AVEN:Berne) a publicly quoted cleantech company, which raised over USD 160m during his time as board member. Patrik's articles have been published in a number of scientific journals including "Nature Biotechnology", "Chimia" and other business publications ("Starting a Business in the Life Sciences: From Idea to Market" and "Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies"). He has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.






Once you are ready to embark on your fundraising campaign, how do you know whom to target? What investors are a best fit for you, how do different investors invest and partner, and how do you get in touch with them? Identifying investors, learning about the differences between investor types, accessing a database to provide you with key information to filter your best fit investors, and finally, using a CRM to manage your fundraiser are critical to an efficient and successful fundraiser.



Claire Jeong, VP, Investor Research & Asia Business Development, Life Science Nation
At Life Science Nation (LSN), Claire leads the Investor Research team that is responsible for curating the LSN Investor Platform. Claire manage relationships with a wide network of investors, pharmaceuticals, and other strategic partners across the globe. As Asia BD, Claire is responsible for building LSN's network in Asia with a strong focus in South Korea and Japan. Since 2018, she has been working with numerous organizations in South Korea, leading collaboration efforts to bring a large delegation of Korean start-ups to the Redefining Early Stage Investments (RESI) Conference, an early-stage life science investment focused partnering conference organized by LSN, supporting their global expansion efforts. Claire is also heavily involved with RESI strategy and program development, for which she works on structuring relevant content and work closely with many investors on this front. Claire is also the team lead for the Innovator's Pitch Challenge (IPC) and oversees all logistics.



Karen Deyo, VP of Product, Israel Business Development, Life Science Nation

Karen Deyo is an Investor Research Analyst at Life Science Nation. In addition to her role curating the LSN Investor Database, she is actively involved in Israel BD, utilizing her professional and personal connections to connect LSN to the Israeli life sciences startup community. Karen has a Masters of Engineering in Biomedical Engineering as well as a Certificate in Graduate Business Study from Worcester Polytechnic Institute and a Bachelor of Science degree in Engineering with a concentration in Bioengineering from Olin College of Engineering.



RESI REDEFINING
EARLY STAGE
INVESTMENTS

CONFERENCE SERIES



RESI BOSTON 2024

SEPT. 25 BOSTON, MA
SEPT. 26 - 27 VIRTUAL PARTNERING



PRESENTED BY

TITLE SPONSORS



Take **\$100** off with discount code **RESI100**

For more information about our future events,
visit our website RESIConference.com or contact us at RESI@lifesciencenation.com.